Close Menu

Zinfandel

Allen Roses Dies

Duke University's Allen Roses, known for his Alzheimer's disease research and more, has died.

Experts led by Duke neuroscientist Allen Roses developed the database hoping to boost researchers' ability to explore the role of short structural variants in complex diseases. 

The group demonstrated the ability of a genetic algorithm to gauge whether cognitively normal people are at risk of near-term mental decline.

NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations.

This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3.

Industry reactions to the US Supreme Court's decision to invalidate patents on isolated gene sequences were immediate and ranged from elation to disappointment.

Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.

Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.

Pages

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.